Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vena Cava Filters | 17 | 2020 | 86 | 6.110 |
Why?
|
| Device Removal | 18 | 2020 | 163 | 4.360 |
Why?
|
| Vena Cava, Inferior | 12 | 2022 | 140 | 4.010 |
Why?
|
| Pulmonary Embolism | 10 | 2020 | 230 | 2.260 |
Why?
|
| Prosthesis Implantation | 5 | 2020 | 130 | 2.150 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2024 | 410 | 1.990 |
Why?
|
| Liver Neoplasms | 9 | 2024 | 767 | 1.840 |
Why?
|
| Venous Thrombosis | 8 | 2022 | 253 | 1.620 |
Why?
|
| Embolization, Therapeutic | 10 | 2024 | 260 | 1.270 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2022 | 31 | 1.240 |
Why?
|
| Catheter Ablation | 2 | 2022 | 254 | 1.060 |
Why?
|
| Treatment Outcome | 31 | 2024 | 8740 | 0.960 |
Why?
|
| Radiography, Interventional | 9 | 2019 | 144 | 0.850 |
Why?
|
| Cholecystostomy | 1 | 2020 | 3 | 0.700 |
Why?
|
| Cholecystitis, Acute | 1 | 2020 | 8 | 0.700 |
Why?
|
| Foreign-Body Migration | 1 | 2020 | 34 | 0.670 |
Why?
|
| Surgical Instruments | 1 | 2020 | 61 | 0.660 |
Why?
|
| Phlebography | 7 | 2017 | 65 | 0.660 |
Why?
|
| Prosthesis Design | 8 | 2019 | 303 | 0.640 |
Why?
|
| Liver Transplantation | 7 | 2013 | 1186 | 0.630 |
Why?
|
| Renal Dialysis | 6 | 2007 | 340 | 0.630 |
Why?
|
| Aorta | 1 | 2020 | 291 | 0.610 |
Why?
|
| Retrospective Studies | 21 | 2024 | 9703 | 0.590 |
Why?
|
| Stents | 3 | 2013 | 417 | 0.570 |
Why?
|
| Hemorrhage | 1 | 2019 | 291 | 0.560 |
Why?
|
| Yttrium Radioisotopes | 7 | 2024 | 46 | 0.540 |
Why?
|
| Microspheres | 3 | 2024 | 101 | 0.540 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 456 | 0.520 |
Why?
|
| Jugular Veins | 2 | 2014 | 74 | 0.510 |
Why?
|
| Femoral Vein | 2 | 2014 | 42 | 0.500 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2006 | 42 | 0.490 |
Why?
|
| Endovascular Procedures | 2 | 2022 | 309 | 0.470 |
Why?
|
| Middle Aged | 29 | 2024 | 27030 | 0.460 |
Why?
|
| Microwaves | 1 | 2014 | 34 | 0.460 |
Why?
|
| Vena Cava, Superior | 3 | 2014 | 60 | 0.460 |
Why?
|
| Vascular Diseases | 2 | 2014 | 120 | 0.460 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 77 | 0.460 |
Why?
|
| Radiopharmaceuticals | 2 | 2024 | 193 | 0.450 |
Why?
|
| Bile Duct Neoplasms | 3 | 2024 | 90 | 0.450 |
Why?
|
| Tumor Burden | 2 | 2024 | 314 | 0.450 |
Why?
|
| Brachiocephalic Veins | 1 | 2014 | 33 | 0.440 |
Why?
|
| Catheters, Indwelling | 4 | 2013 | 113 | 0.440 |
Why?
|
| Humans | 54 | 2024 | 92337 | 0.430 |
Why?
|
| Catheterization, Central Venous | 3 | 2013 | 115 | 0.420 |
Why?
|
| Aged | 20 | 2024 | 19943 | 0.410 |
Why?
|
| Time Factors | 10 | 2024 | 5430 | 0.410 |
Why?
|
| Female | 32 | 2024 | 47893 | 0.380 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 6916 | 0.370 |
Why?
|
| Iatrogenic Disease | 2 | 2022 | 71 | 0.360 |
Why?
|
| Embolic Protection Devices | 1 | 2011 | 9 | 0.360 |
Why?
|
| Iliac Vein | 1 | 2011 | 31 | 0.360 |
Why?
|
| Male | 31 | 2024 | 43925 | 0.350 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2011 | 44 | 0.350 |
Why?
|
| Portal Vein | 2 | 2013 | 121 | 0.350 |
Why?
|
| Thrombectomy | 4 | 2022 | 197 | 0.350 |
Why?
|
| Hepatic Artery | 3 | 2021 | 83 | 0.350 |
Why?
|
| Bariatric Surgery | 2 | 2011 | 206 | 0.340 |
Why?
|
| Hepatic Duct, Common | 1 | 2009 | 10 | 0.320 |
Why?
|
| Biliary Fistula | 1 | 2009 | 11 | 0.320 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2007 | 70 | 0.320 |
Why?
|
| Disease Progression | 1 | 2024 | 1503 | 0.320 |
Why?
|
| Angioplasty, Balloon | 2 | 2007 | 98 | 0.320 |
Why?
|
| Anticoagulants | 5 | 2020 | 443 | 0.300 |
Why?
|
| Adult | 19 | 2024 | 27532 | 0.300 |
Why?
|
| Liver Cirrhosis | 2 | 2009 | 269 | 0.300 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 164 | 0.300 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 245 | 0.290 |
Why?
|
| Chicago | 3 | 2019 | 1466 | 0.270 |
Why?
|
| Arm | 1 | 2007 | 96 | 0.270 |
Why?
|
| Risk Factors | 5 | 2024 | 5704 | 0.260 |
Why?
|
| Aneurysm, False | 3 | 2013 | 54 | 0.250 |
Why?
|
| Ischemia | 1 | 2007 | 254 | 0.240 |
Why?
|
| Thrombolytic Therapy | 3 | 2020 | 251 | 0.240 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 227 | 0.230 |
Why?
|
| Prosthesis Failure | 3 | 2014 | 118 | 0.220 |
Why?
|
| Postoperative Complications | 5 | 2013 | 2458 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2021 | 2680 | 0.200 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 3775 | 0.200 |
Why?
|
| Hepatectomy | 1 | 2024 | 176 | 0.200 |
Why?
|
| Constriction, Pathologic | 5 | 2022 | 219 | 0.200 |
Why?
|
| Cholangiography | 2 | 2005 | 39 | 0.190 |
Why?
|
| Propensity Score | 1 | 2022 | 165 | 0.190 |
Why?
|
| Fistula | 1 | 2021 | 42 | 0.180 |
Why?
|
| Bile | 1 | 2001 | 60 | 0.180 |
Why?
|
| Tokyo | 1 | 2020 | 3 | 0.180 |
Why?
|
| Adolescent | 9 | 2021 | 9504 | 0.170 |
Why?
|
| Mechanical Thrombolysis | 1 | 2020 | 16 | 0.170 |
Why?
|
| Vascular Patency | 5 | 2022 | 127 | 0.160 |
Why?
|
| Brachytherapy | 1 | 2021 | 122 | 0.160 |
Why?
|
| Hypotension | 1 | 2020 | 71 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2019 | 36 | 0.160 |
Why?
|
| Catheterization | 3 | 2008 | 238 | 0.160 |
Why?
|
| Radiation Exposure | 1 | 2019 | 24 | 0.160 |
Why?
|
| Equipment Safety | 2 | 2011 | 32 | 0.160 |
Why?
|
| Mortality | 1 | 2020 | 150 | 0.160 |
Why?
|
| Renal Veins | 2 | 2017 | 29 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 230 | 0.150 |
Why?
|
| Anesthesia, General | 1 | 2019 | 119 | 0.150 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 67 | 0.150 |
Why?
|
| Radiography | 4 | 2013 | 795 | 0.150 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 151 | 0.150 |
Why?
|
| Young Adult | 5 | 2021 | 6624 | 0.140 |
Why?
|
| Recurrence | 1 | 2020 | 1180 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 963 | 0.130 |
Why?
|
| Pipecolic Acids | 2 | 2006 | 14 | 0.130 |
Why?
|
| Length of Stay | 1 | 2020 | 798 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2013 | 2369 | 0.130 |
Why?
|
| Fluoroscopy | 1 | 2016 | 132 | 0.130 |
Why?
|
| Anastomosis, Surgical | 2 | 2009 | 280 | 0.130 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2007 | 99 | 0.130 |
Why?
|
| Thrombin | 2 | 2013 | 60 | 0.120 |
Why?
|
| Hemostatics | 2 | 2013 | 59 | 0.120 |
Why?
|
| Angioplasty | 2 | 2013 | 71 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 156 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1919 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2006 | 244 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2013 | 74 | 0.100 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 34 | 0.100 |
Why?
|
| Abdominal Injuries | 1 | 2013 | 51 | 0.100 |
Why?
|
| Foreign Bodies | 1 | 2013 | 65 | 0.100 |
Why?
|
| Endoleak | 1 | 2012 | 41 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 115 | 0.090 |
Why?
|
| Contraindications | 1 | 2011 | 70 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2011 | 800 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 120 | 0.090 |
Why?
|
| Child, Preschool | 5 | 2006 | 3818 | 0.090 |
Why?
|
| Survival Rate | 1 | 2014 | 1927 | 0.090 |
Why?
|
| Renal Artery | 1 | 2010 | 50 | 0.080 |
Why?
|
| Plasma | 2 | 2007 | 51 | 0.080 |
Why?
|
| Equipment Design | 1 | 2011 | 418 | 0.080 |
Why?
|
| Portal System | 1 | 2009 | 13 | 0.080 |
Why?
|
| Balloon Occlusion | 1 | 2009 | 30 | 0.080 |
Why?
|
| Liver Failure | 1 | 2009 | 69 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2009 | 111 | 0.080 |
Why?
|
| Contrast Media | 3 | 2013 | 1076 | 0.070 |
Why?
|
| Alloys | 1 | 2007 | 10 | 0.070 |
Why?
|
| Axillary Vein | 1 | 2007 | 5 | 0.070 |
Why?
|
| Nephrectomy | 1 | 2010 | 294 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 37 | 0.070 |
Why?
|
| Hemostasis | 1 | 2007 | 22 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2009 | 246 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2011 | 800 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2007 | 44 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2007 | 89 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2006 | 9 | 0.070 |
Why?
|
| Thrombosis | 2 | 2006 | 312 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2007 | 56 | 0.070 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2006 | 35 | 0.070 |
Why?
|
| Dilatation | 1 | 2006 | 49 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2006 | 96 | 0.060 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2006 | 5 | 0.060 |
Why?
|
| Potassium | 5 | 1990 | 261 | 0.060 |
Why?
|
| Mesenteric Arteries | 1 | 2006 | 29 | 0.060 |
Why?
|
| Bacteremia | 1 | 2007 | 105 | 0.060 |
Why?
|
| Angiography | 2 | 2021 | 205 | 0.060 |
Why?
|
| Microfluidics | 1 | 2006 | 55 | 0.060 |
Why?
|
| Spasm | 1 | 2005 | 18 | 0.060 |
Why?
|
| Nitroglycerin | 1 | 2005 | 23 | 0.060 |
Why?
|
| Graft Survival | 1 | 2009 | 935 | 0.060 |
Why?
|
| Punctures | 1 | 2005 | 30 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 530 | 0.060 |
Why?
|
| Biliary Tract Diseases | 1 | 2005 | 37 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 145 | 0.060 |
Why?
|
| Retreatment | 2 | 2021 | 107 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2024 | 67 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 279 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2024 | 35 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2368 | 0.050 |
Why?
|
| Research Design | 1 | 2007 | 600 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 209 | 0.050 |
Why?
|
| Venous Pressure | 1 | 2002 | 11 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2005 | 206 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 810 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2005 | 256 | 0.050 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2001 | 25 | 0.050 |
Why?
|
| Catheterization, Peripheral | 1 | 2001 | 62 | 0.040 |
Why?
|
| Age Factors | 1 | 2005 | 1905 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 245 | 0.040 |
Why?
|
| Drainage | 1 | 2001 | 169 | 0.040 |
Why?
|
| Erythrocyte Membrane | 2 | 1990 | 61 | 0.040 |
Why?
|
| Erythrocytes | 2 | 1989 | 251 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2002 | 756 | 0.040 |
Why?
|
| Infant | 3 | 2013 | 3218 | 0.040 |
Why?
|
| Arginine | 2 | 2006 | 140 | 0.030 |
Why?
|
| Chlorides | 3 | 1989 | 104 | 0.030 |
Why?
|
| Sulfonamides | 2 | 2006 | 328 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1592 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2005 | 97 | 0.030 |
Why?
|
| Child | 4 | 2006 | 7334 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 128 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 289 | 0.020 |
Why?
|
| Sodium | 2 | 1990 | 335 | 0.020 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1989 | 12 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 987 | 0.020 |
Why?
|
| Ion Channels | 1 | 1990 | 251 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1661 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2009 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 1989 | 145 | 0.020 |
Why?
|
| Phospholipids | 1 | 2007 | 112 | 0.020 |
Why?
|
| Hemofiltration | 1 | 2006 | 9 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2007 | 148 | 0.020 |
Why?
|
| Titrimetry | 1 | 2006 | 15 | 0.020 |
Why?
|
| Duodenum | 1 | 2007 | 105 | 0.020 |
Why?
|
| Radiology, Interventional | 1 | 2006 | 63 | 0.020 |
Why?
|
| Life Tables | 1 | 2005 | 47 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 416 | 0.020 |
Why?
|
| Ointments | 1 | 2005 | 12 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2005 | 52 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2794 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2007 | 114 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2005 | 61 | 0.020 |
Why?
|
| Femur | 1 | 2005 | 107 | 0.010 |
Why?
|
| Arteries | 1 | 2005 | 179 | 0.010 |
Why?
|
| Biological Transport | 3 | 1989 | 410 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 174 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1398 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 416 | 0.010 |
Why?
|
| Reoperation | 1 | 2005 | 654 | 0.010 |
Why?
|
| Phlebotomy | 1 | 2001 | 22 | 0.010 |
Why?
|
| Collateral Circulation | 1 | 2001 | 38 | 0.010 |
Why?
|
| Veins | 1 | 2001 | 96 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 2517 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7348 | 0.010 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 2 | 1989 | 3 | 0.010 |
Why?
|
| Methazolamide | 2 | 1989 | 3 | 0.010 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 2 | 1989 | 18 | 0.010 |
Why?
|
| Sheep | 2 | 1990 | 249 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 708 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1989 | 501 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1990 | 120 | 0.010 |
Why?
|
| Cations | 1 | 1989 | 31 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1989 | 145 | 0.010 |
Why?
|
| Permeability | 1 | 1989 | 141 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1989 | 112 | 0.010 |
Why?
|
| Hemoglobin SC Disease | 1 | 1989 | 1 | 0.010 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 1989 | 4 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1989 | 67 | 0.000 |
Why?
|
| Dogs | 1 | 1990 | 705 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1989 | 402 | 0.000 |
Why?
|
| Bumetanide | 1 | 1988 | 4 | 0.000 |
Why?
|
| Membrane Potentials | 1 | 1990 | 436 | 0.000 |
Why?
|
| Anions | 1 | 1988 | 31 | 0.000 |
Why?
|
| Ouabain | 1 | 1988 | 24 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1988 | 102 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1988 | 181 | 0.000 |
Why?
|
| Hemolysis | 1 | 1988 | 62 | 0.000 |
Why?
|
| Furosemide | 1 | 1988 | 36 | 0.000 |
Why?
|
| Rabbits | 1 | 1989 | 644 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1989 | 997 | 0.000 |
Why?
|
| Kinetics | 1 | 1988 | 1550 | 0.000 |
Why?
|
| Calcium | 1 | 1989 | 1183 | 0.000 |
Why?
|
| Animals | 2 | 1990 | 28003 | 0.000 |
Why?
|